| 000 | 01834 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515174857.0 | ||
| 264 | 0 | _c20091112 | |
| 008 | 200911s 0 0 eng d | ||
| 022 | _a1865-3774 | ||
| 024 | 7 |
_a10.1007/s12185-009-0370-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTeshima, Takanori | |
| 245 | 0 | 0 |
_aRituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. _h[electronic resource] |
| 260 |
_bInternational journal of hematology _cSep 2009 |
||
| 300 |
_a253-260 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdrenal Cortex Hormones _xtherapeutic use |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies _xblood |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 | _aChronic Disease |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGraft vs Host Disease _xdrug therapy |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aNagafuji, Koji | |
| 700 | 1 | _aHenzan, Hideho | |
| 700 | 1 | _aMiyamura, Koichi | |
| 700 | 1 | _aTakase, Ken | |
| 700 | 1 | _aHidaka, Michihiro | |
| 700 | 1 | _aMiyamoto, Toshihiro | |
| 700 | 1 | _aTakenaka, Katsuto | |
| 700 | 1 | _aAkashi, Koichi | |
| 700 | 1 | _aHarada, Mine | |
| 773 | 0 |
_tInternational journal of hematology _gvol. 90 _gno. 2 _gp. 253-260 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s12185-009-0370-x _zAvailable from publisher's website |
| 999 |
_c18961939 _d18961939 |
||